Genmab’s Phase 3 RAINFOL-02 Trial Meets Primary PFS And Key Secondary OS Endpoints, Demonstrating A Statistically Significant And Clinically Meaningful Improvement For Rina-S In Platinum-Resistant Ovarian Cancer

뉴스 본문을 불러오고 있어요.

Genmab’s Phase 3 RAINFOL-02 Trial Meets Primary PFS And Key Secondary OS Endpoints, Demonstrating A Statistically Significant And Clinically Meaningful Improvement For Rina-S In Platinum-Resistant Ovarian Cancer | 웨이프 WAPE

Genmab’s Phase 3 RAINFOL-02 Trial Meets Primary PFS And Key Secondary OS Endpoints, Demonstrating A Statistically Significant And Clinically Meaningful Improvement For Rina-S In Platinum-Resistant Ovarian Cancer

기사 요약

관련 종목

댓글 —